Background Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid
receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and …

An increasing number of individuals are at high risk of type 2 diabetes (T2D) and its
cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD) …

Importance Albuminuria, routinely assessed as spot urine albumin-to-creatinine ratio
(UACR), indicates structural damage of the glomerular filtration barrier and is associated …

Two novel treatments for diabetic kidney disease have emerged after decades with little
progression. Both agents were developed for improved glycemic control in patients with type …

Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body
weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to …

Aims Diabetes is associated with a faster rate of renal function decline in patients with heart
failure (HF). Sacubitril/valsartan attenuates the deterioration of renal function to a greater …

BACKGROUND Sodium glucose cotransporter-2 inhibitors (SGLT-2i) are a class of drugs
with modest antidiabetic efficacy, weight loss effect, and cardiovascular benefits as proven …

Sodium-glucose cotransporter 2 inhibitors slow progressive loss of kidney function in
patients with type 2 diabetes across a wide range of eGFR and albuminuria. In the …

Abstract Sodium‐glucose cotransporter (SGLT)‐2 inhibitors have recently been approved for
chronic kidney disease (CKD) based on their ability to lower proteinuria and slow CKD …

Sodium glucose cotransporter-2 inhibitors (SGLT-2i) are antidiabetic medications with
remarkable cardiovascular (CV) benefits proven by multiple randomised controlled trials and …